Table 1.
Selected Baseline Characteristics of the Study Participants (n=92,980)*
| Characteristic | Number (%) |
|---|---|
| Age, years | |
| 50–59 | 29457 (31.68%) |
| 60–69 | 40926 (44.02%) |
| 70–79 | 22597 (24.30%) |
| Age (years)† | 63.62 +/−7.37 |
| Race / ethnicity | |
| White | 77607 (83.47%) |
| Black | 7516 (8.08%) |
| Hispanic | 3499 (3.76%) |
| Other | 4358 (4.69%) |
| Education | |
| ≤ High school/GED or less | 19725 (21.39%) |
| School after high school | 33700 (36.54%) |
| College Degree or higher | 38800 (42.07%) |
| Body mass index (kg/m2)‡ | 27.26+/− 5.86 |
| Smoking status | |
| Never | 46736 (50.93%) |
| Past | 39303 (42.83%) |
| Current | 5735 (6.25%) |
| Alcohol consumption | |
| Non/past drinker | 27757 (30.04%) |
| <1 drink/week | 29263 (31.67%) |
| 1–14 drinks/week | 31374 (33.95%) |
| >14 drinks/week | 4016 (4.35%) |
| Total calcium (mg/d)§ | 1241.6 +/− 769.8 |
| Total vitamin D (IU/d)** | 389.85 +/−286.7 |
| Total energy expenditure/week from physical activities (MET-hours)†† | 13.71 +/−14.36 |
| History of fracture age 55+ | |
| Under age 55 when filled out the form | 12568 (14.60%) |
| No | 61046 (70.90%) |
| Yes | 12490 (14.51%) |
| Parental history of fracture | |
| None | 58798 (63.24%) |
| One parent | 31177 (33.53%) |
| Both parents | 3005 (3.23%) |
| Number of falls in the past 12 months | |
| None | 62235 (67.68%) |
| 1 time | 18306 (19.91%) |
| 2 times | 7533 (8.19%) |
| 3 or more times | 3879 (4.22%) |
| Menopausal Hormone Use | |
| Never used | 37655 (40.53%) |
| Past user | 13846 (14.90%) |
| Current user | 41395 (44.56%) |
| Route of estrogen delivery | |
| Never used | 37655 (43.67%) |
| Former | 13840 (16.05%) |
| Oral E+P | 13145 (15.24%) |
| Oral CEE alone | 16412 (19.03%) |
| Oral estradiol | 3007 (3.49%) |
| Transdermal estradiol | 2176 (2.52%) |
| Recency of estrogen use (years) | |
| Non User | 37655 (40.53%) |
| Past, < 5 | 5532 (5.96%) |
| Past, 5–<10 | 2557 (2.75%) |
| Past, >10 | 5757 (6.20%) |
| Current | 41395 (44.56%) |
| Bisphosphonates | 2318 (2.49%) |
| Selective estrogen receptor modulators | 38 (0.04%) |
| Calcitonin | 355 (0.38%) |
| Aromatase inhibitors | 7 (0.01%) |
| Tamoxifen | 1021 (1.10%) |
| Antidepressants | 6978 (7.50%) |
| Glucocorticoid | 1256 (1.35%) |
| Proton Pump Inhibitors | 2109 (2.27%) |
| Anti-epileptics | 1041 (1.12%) |
| Anti-neoplastics | 1525 (1.64%) |
| Thiazolidinediones | 88 (0.09%) |
| Weight history | |
| Weight at age 35 (lbs)‡‡ | 131.95 +/−20.41 |
| Weight change since age 35 (lbs)§§ | 26.02 +/−29.75 |
| Maximum adult weight (lbs)*** | 163.43 +/−35.34 |
| Minimum adult weight (lbs)††† | 118.10 +/−16.86 |
*
Baseline characteristics unless otherwise stated
†
Values are mean +/− standard deviation (SD).
‡
Values are mean +/− SD.
§
Includes total intake from both diet and supplements. Values are mean +/− SD.
**
Includes total intake from both diet and supplements. Values are mean +/− SD.
††
Values are mean +/− SD.
‡‡
Values are mean +/− SD.
§§
Values are mean +/− SD.
***
Values are mean +/− SD.
†††
Values are mean +/− SD.